Assembly Biosciences Aktie (A117S1 | ASMB

Was macht Assembly Biosciences?

Unternehmensprofil

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Chart der Assembly Biosciences Aktie

Charttool öffnen

Aktuelle Nachrichten zu Assembly Biosciences

Weitere Nachrichten

Das berichten andere über Assembly Biosciences

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript

Assembly Biosciences stock initiated at Market Outperform by JMP By Investing.com

Assembly Biosciences stock initiated at Market Outperform by JMP

Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains?

Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue...

Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?

Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue...